Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07089355

Study Evaluating Toro 88 Super Bore Aspiration Catheter for Acute Ischemic Stroke

The goal of this pilot study is to evaluate the safety and efficacy of the Toro 88 Super Bore Aspiration Catheter in acute ischemic stroke patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

This is a prospective, open-label, single-arm, single-center clinical investigation evaluating the safety and efficacy of the Toro 88 Super Bore Aspiration Catheter in mechanical thrombectomy for acute ischemic stroke. The study is being conducted at the Hôpital Fondation Adolphe de Rothschild in France.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged ≥ 18 and ≤ 90 years at the time of consent
  • Presenting with an acute ischaemic stroke for which symptoms (or last time seen as normal) are < 24h
  • With occlusion of the ICA / the M1 segment of the MCA / a vertebral artery diameter ≥3.5mm / the basilar artery, defined by eTICI≤1
  • Requiring endovascular treatment (mechanical thrombectomy) with or without intravenous thrombolysis
  • For whom the experimental device is the first-line treatment
  • Without pre-existing disability (mRS ≤3 and 6≤ NIHSS ≤30 before stroke)
  • Informed consent signed :
  • By the patient
  • Or consent by a family member/trusted support person if the patient's condition does not allow them to express their consent in writing (L1111-6)

Exclusion criteria

  • Arterial dissection
  • Suspicion of vasculitis
  • Suspected intracranial stenosis near the occlusion site
  • Concomitant intracranial haemorrhage
  • Known coagulation disorder
  • Known coagulopathy
  • Known platelet count <50,000/μL
  • Significant mass effect with midline shift
  • Suspicion or evidence of aortic dissection, septic embolus, or bacterial endocarditis
  • INR ≥ 3.0
  • APTT ≥ 2 times normal
  • Systolic blood pressure > 185 mmHg and/or diastolic blood pressure < 110 mmHg
  • Blood glucose < 50 mg/dL or >400 mg/dL according to the last measurement taken before the procedure
  • Known allergy to contrast media
  • Occluded arteries in more than one large vascular territory (at least two of the left and right internal carotid arteries or the territory of a carotid artery and an artery of the vertebrobasilar system).
  • Pregnant or breast-feeding women (urine or serum pregnancy test negative at inclusion).
  • Adults under legal protection (L1121-8)
  • Persons deprived of their liberty by judicial or administrative decision, persons under psychiatric care under articles L3212-1 and L3123-1 and persons admitted to a health or social establishment for purposes other than research (L1121-6).
  • Participation in other interventional clinical research

Treatment and study plan

Toro 88 Super Bore Aspiration Catheter

Device

The Toro 88 Super Bore Aspiration Catheter is a neurovascular device designed for clot aspiration during mechanical thrombectomy procedures.

Primary outcomes

  1. Incidence of adverse events that may be associated with the use of the experimental device at 24-36h

    Time frame: From start of procedure to 24-36 hours post-procedure

Secondary outcomes

  1. eTICI score ≥ 2b50 after a maximum of 3 passages with the experimental device

    Time frame: Immediately after final device pass (intra-procedural)

  2. Lesion site reached according to the operator

    Time frame: Intra-procedural

  3. eTICI score ≥ 2c after the first pass with the experimental device

    Time frame: Immediately after first device pass (intra-procedural)

  4. eTICI score ≥ 2b67 after the first pass with the experimental device

    Time frame: Immediately after first device pass (intra-procedural)

  5. Symptomatic intracranial haemorrhage

    Time frame: 22 to 36 hours after reperfusion

    Symptomatic intracranial haemorrhage according to the SITS-MOST definition (Lancet 2007) : occurrence of an intraparenchymal haematoma (PH-2) on imaging, within 22-36 hours after reperfusion treatment, associated with a clinical worsening defined by a worsening of at least 4 NIHSS points.

  6. All adverse events

    Time frame: From procedure to 90 days post-procedure

  7. NIHSS score

    Time frame: At discharge and at 90 days post-procedure

  8. All serious adverse events

    Time frame: From procedure to 90 days post-procedure

  9. All-cause death

    Time frame: From procedure to 90 days post-procedure

  10. Modified Rankin Score (mRS) ≤ 2

    Time frame: At 90 days post-procedure

Study contacts

Contact information is provided by the study sponsor or research team.

Cheffe de Service

CONTACT

[email protected]

+33 01 48 03 64 54

Sponsors and collaborators

Lead sponsor

Toro Neurovascular, Inc.

Industry

Registry information

Official study title

Open-Label, Single-Arm Study Evaluating Toro 88 Super Bore Aspiration Catheter Safety and Efficacy in Mechanical Thrombectomy for Acute Ischemic Stroke in France

Acronym: TORO EFFECT FR

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Jul 28, 2025
Registry last updated
Jul 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.